ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2221

Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers

Lourdes Ladehesa Pineda1, Ivan Arias de la Rosa2, Laura Cuesta-López3, Clementina López Medina4, María Ángeles Puche Larrubia5, Miriam Ruiz-Ponce3, María del carmen Ábalos Aguilera3, Pedro Ortiz Buitrago3, Yasin Hanaee3, Carlos Perez-Sanchez6, Chary López-Pedrera3, Alejandro Escudero-Contreras7, Eduardo Collantes Estévez8 and Nuria Barbarroja9, 1Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, 3IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 4Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, 5Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, 6IMIBIC, Córdoba, Spain, 7Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, 8Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, 9University of Cordoba, Córdoba, Spain

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Cardiovascular, Inflammation, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Chronic inflammation is closely associated with an increased risk of cardiovascular diseases (CVD) through the activation of the immune system and the release of inflammatory molecules like C-reactive protein (CRP). In Spondyloarthritis (SpA), prolonged inflammation can harm the vascular system, further raising the likelihood of developing CVD. Currently, there is a lack of tools available to identify patients who had persistent inflammation and its connection to CVD. The aim of this study was to analyze the clinical and molecular characteristics associated with persistent inflammation and to identify potential plasma protein biomarkers for an easy identification of patients with prolonged inflammation over the years in SpA patients

Methods: A study involving 136 patients diagnosed with SpA was conducted. Clinical and laboratory parameters, as well as CVD risk factors were recorded. To assess the presence of persistent inflammation, levels of CRP were retrospectively collected for a period of 5 years. A patient was classified as having persistent inflammation if increased CRP levels were detected in at 100% of the measurements taken during the preceding 5-year timeframe. Radiographs of the cervical spine, lumbar spine, and sacroiliac joints were obtained. Lateral views of the cervical and lumbar spine were scored according to the mSASSS index. Sacroiliitis was scored from right side and left side pelvic radiographs using the modified New York criteria. The plasma levels of 92 proteins related to CVD were analyzed using proximity extension assay (PEA) technology (Olink Target 96 CVD III panel, Cobiomic Biosciences).

Results: 36% of SpA patients had persistence of inflammation. Clinically, these patients showed higher levels of disease activity (ASDAS), peripheral forms, structural damage (mSASSS), acute phase reactants, altered metabolic profile, activation of complement component and higher rates of cardiometabolic comorbidities compared to non-persistent SpA patients. At molecular level, 16 CVD-related plasma proteins were significantly associated with presence of persistence of inflammation: MMP-9, RETN, PGLYRP-1, UPAR, PRTN-3, TR, RARRES-2, AZU-1, GP-6, TNF-R1, MPO, GDF-15, CCL-16, IL-2RA, PI3 and PDGF. The most contributing proteins to differentiate groups of SpA patients with persistent and non-persistent inflammation were MMP-9, RETN, PGLYRP-1 and UPAR. The combination of these proteins could predict the presence of constant persistent inflammation with an AUC=0.865. These proteins exhibit specific biological functions such as neutrophil degranulation, immune response, leukocyte migration and apoptosis.

Conclusion: 1) persistent inflammation over five years was associated with peripheral forms, increased disease activity and radiographical damage in SpA patients. 2) SpA patients with persistent inflammation display a pronounced alteration in their plasma CVD protein profile, indicating a connection between subclinical CVD risk and chronic inflammation. 3) we identified novel biomarkers that have the potential to differentiate SpA patients with persistent inflammation, offering valuable insights for therapeutic approaches.
Funded by ISCIII (PMP21/00119).


Disclosures: L. Ladehesa Pineda: None; I. Arias de la Rosa: None; L. Cuesta-López: None; C. López Medina: AbbVie, 5, 6, Eli Lilly, 2, 5, 6, Janssen, 6, MSD, 6, Novartis, 2, 5, 6, UCB Pharma, 2, 5, 6; M. Puche Larrubia: None; M. Ruiz-Ponce: None; M. Ábalos Aguilera: None; P. Ortiz Buitrago: None; Y. Hanaee: None; C. Perez-Sanchez: None; C. López-Pedrera: None; A. Escudero-Contreras: None; E. Collantes Estévez: None; N. Barbarroja: None.

To cite this abstract in AMA style:

Ladehesa Pineda L, Arias de la Rosa I, Cuesta-López L, López Medina C, Puche Larrubia M, Ruiz-Ponce M, Ábalos Aguilera M, Ortiz Buitrago P, Hanaee Y, Perez-Sanchez C, López-Pedrera C, Escudero-Contreras A, Collantes Estévez E, Barbarroja N. Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinical-and-molecular-patterns-associated-with-persistence-of-inflammation-in-spondyloarthritis-patients-unveiling-potential-biomarkers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-molecular-patterns-associated-with-persistence-of-inflammation-in-spondyloarthritis-patients-unveiling-potential-biomarkers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology